Navigation Links
"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila
Date:7/30/2009

TOKYO, July 30 /PRNewswire/ -- With a business plan to launch 8-10 new products each year, Nippon Universal Pharmaceutical Co. Ltd., a subsidiary of the Zydus group, one of India's leading integrated pharma companies & a global healthcare provider, is looking to give a big boost to its operations in the Japanese generic market which is still evolving. While the total pharma market in Japan is estimated at $ 60 bn the generic market is only about 6% of this in value terms and just 18% in volume, which is very low compared to highly genericised markets like USA and Europe. The awareness of generics in Japan is comparatively low and generics are still largely perceived as cheaper, low quality alternatives to patented drugs. The nationwide promotion and awareness campaign regarding the safety and efficacy of generics however is expected to change this perception and usage in future.

Zydus was one of the few Indian companies to make an early foray in the Japan generic market. In 2007, the group acquired Nippon Universal, a small generic company which now spearheads the group's operations in Japan.

"Our aim clearly is to support the government's stated objective of increasing generic penetration in order to cope up with ever increasing health expenditures. Over the next 2-3 years we will leverage developmental capabilities and explore in-licensing and a co-development model to consolidate our presence in Japan", said Dr. Kailash Sharma, the newly appointed President to spearhead operations in Japan.

Being one of the few pharma professionals who can combine research, strategy and marketing expertise, Dr. Kailash Sharma is much sought after. Dr. Kailash Sharma with over 13 years of experience in the Japan's pharma industry will be steering the group's operations in this crucial growth phase. With a doctorate in Cell & Molecular Biology from Kurume University Medical School, Japan and an Executive MBA from Temple University, Philadelphia, USA, Dr. Sharma has earlier worked with Eisai, Nippon Boehringer Ingelheim and Sanofi - Aventis, Japan and has successfully managed the core functions in all phases of drug development cycles. Last but not least, being in Japan for about 20 years, first as a doctorate researcher and then as a pharmaceutical professional, Dr. Sharma is very well familiar and have respect for Japanese culture, legal system, quality standards, regulatory guidelines and business practices in Japan.

With a focus on quality medicines, Nippon Universal will be leveraging Zydus' capabilities in oral solids, injectables, biosimilars etc. While ramping up the product pipeline is important, the group's strategy would be more country specific and focus on the unmet needs in the Japanese market. elaborating on the group's approach, Dr. Sharma said "We believe that there is a growing need for high quality, affordable therapies while reducing the healthcare cost burden. We are looking to combine expertise with adaptability. Understanding specific market needs and backing it up with customer centric approach will form the core of our strategy." The group plans to post sales of Yen 20 billion in Japan by 2015.


'/>"/>
SOURCE Zydus Cadila
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
2. Social Network for Scientists Marks Ten Years Online
3. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
4. Dark energy -- 10 years on
5. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
6. Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth
7. Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25% Annually Over the Next Five Years
8. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
9. Graphene-based gadgets may be just years away
10. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
11. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers ... research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of the latest paper by its Science Editor, Dr. Elisabeth Bik, in the ... Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
(Date:1/18/2017)... 2017  Caris Life Sciences, a leading innovator ... largest private funder of pancreatic cancer research, are ... impact of immunotherapy in the treatment of pancreatic ... to identify potential trial candidates based on biomarker ... and study investigators. The Lustgarten Foundation is a ...
Breaking Biology Technology:
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
Breaking Biology News(10 mins):